One study showed dramatic tumor regression in C3-TAg mice following dual treatment of tumor-bearing mice with the drugs AZD6244 (selumetinib) and BEZ235 (dactolisib), resulting in the dual inhibition of PI3K/mTOR and MEK signaling [70]. This evidence concerns the gene MAP2K7 and neoplasm.